MedTrace Logo

CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis

NCT05614817 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2023-03-21

No results posted yet for this study

Summary

This is a Phase 3, randomized, double-blinded, placebo-controlled trial in patients, ≥12 years of age who weigh ≥40 kg, and are diagnosed with moderate-to-severe AD.

Conditions

Interventions

DRUG

CBP-201

CBP-201 subcutaneous(SC) injection

DRUG

Placebo

subcutaneous(SC) injection

Sponsors & Collaborators

  • Connect Biopharm LLC

    lead INDUSTRY

Principal Investigators

  • Suzhou Connect · Connect Biopharm LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-31
Primary Completion
2024-08-31
Completion
2025-07-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05614817 on ClinicalTrials.gov